JP2009534374A - Anti-inflammatory or analgesic composition comprising white flower serpentine extract extract containing ursolic acid and oleanolic acid - Google Patents
Anti-inflammatory or analgesic composition comprising white flower serpentine extract extract containing ursolic acid and oleanolic acid Download PDFInfo
- Publication number
- JP2009534374A JP2009534374A JP2009506406A JP2009506406A JP2009534374A JP 2009534374 A JP2009534374 A JP 2009534374A JP 2009506406 A JP2009506406 A JP 2009506406A JP 2009506406 A JP2009506406 A JP 2009506406A JP 2009534374 A JP2009534374 A JP 2009534374A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- acid
- mushrooms
- inflammatory
- white flower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 90
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 title claims abstract description 77
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 55
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 title claims abstract description 49
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229940096998 ursolic acid Drugs 0.000 title claims abstract description 49
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims abstract description 47
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title claims abstract description 47
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title claims abstract description 47
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229940100243 oleanolic acid Drugs 0.000 title claims abstract description 47
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000001760 anti-analgesic effect Effects 0.000 title claims abstract description 31
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 40
- 239000012264 purified product Substances 0.000 claims description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 16
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 16
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 16
- 239000011425 bamboo Substances 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 235000013376 functional food Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- -1 alcohol ester Chemical class 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 5
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 241000222518 Agaricus Species 0.000 claims description 4
- 240000001080 Grifola frondosa Species 0.000 claims description 4
- 235000007710 Grifola frondosa Nutrition 0.000 claims description 4
- 240000000599 Lentinula edodes Species 0.000 claims description 4
- 230000036592 analgesia Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000012676 herbal extract Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 241000190633 Cordyceps Species 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 150000008282 halocarbons Chemical class 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
- 241001330002 Bambuseae Species 0.000 claims 10
- 235000013365 dairy product Nutrition 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 description 56
- 230000000694 effects Effects 0.000 description 25
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 24
- 229960001680 ibuprofen Drugs 0.000 description 24
- 208000002193 Pain Diseases 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 16
- 210000002683 foot Anatomy 0.000 description 15
- 210000000278 spinal cord Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 230000036407 pain Effects 0.000 description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 210000004712 air sac Anatomy 0.000 description 13
- 230000006698 induction Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000000202 analgesic effect Effects 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 208000038016 acute inflammation Diseases 0.000 description 7
- 230000006022 acute inflammation Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010030124 Oedema peripheral Diseases 0.000 description 6
- 244000082204 Phyllostachys viridis Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000000416 exudates and transudate Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 230000008468 bone growth Effects 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229920000392 Zymosan Polymers 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000001659 Oldenlandia diffusa Species 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000121220 Tricholoma matsutake Species 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000111261 Mucuna pruriens Species 0.000 description 1
- 235000006161 Mucuna pruriens Nutrition 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241001261543 Orthriophis moellendorffi Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 229940082151 ibuprofen 100 mg Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000000955 oleanolic acid group Chemical group 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物を含む消炎用または鎮痛用の組成物が開示される。前記白花蛇舌草抽出精製物のウルソール酸及びオレアノール酸の含量は80〜95重量%であり、前記ウルソール酸:オレアノール酸の割合は1:0.05〜0.6であることを特徴とする。 An anti-inflammatory or analgesic composition comprising a purified white flower serpentine grass extract containing ursolic acid and oleanolic acid is disclosed. The ursolic acid and oleanolic acid content of the white flower serpentine extract is 80 to 95% by weight, and the ursolic acid: oleanolic acid ratio is 1: 0.05 to 0.6. .
Description
本発明はウルソール酸及びオレアノール酸を含有する白花蛇舌草(Oldenlandia diffusa)抽出精製物を含む消炎または鎮痛用の組成物に関する。 The present invention relates to an anti-inflammatory or analgesic composition comprising a purified extract of Oldenlandia diffusa containing ursolic acid and oleanolic acid.
難治性炎症性疾患のうち代表的なリウマチ関節炎は関節腔内に炎症細胞の浸潤による異常免疫反応により誘発される自家免疫性炎症疾患であって、激しい痛みと関節の変形、及び機能の消失を特徴としている。このため、臨床において用いられる関節炎治療の原則は、痛みと炎症を抑制して関節の機能消失を極力抑えることを目指している。関節炎に対する一次的な薬物治療療法として、アスピリンなどの非ステロイド性(NSAIDs)消炎剤と低容量経口ステロイド性免疫抑制剤であるメトトレキサート及びイムランなどが用いられ、場合によって、関節腔内にステロイド剤を注射している。 Rheumatoid arthritis, which is a typical intractable inflammatory disease, is an autoimmune inflammatory disease induced by an abnormal immune reaction caused by the infiltration of inflammatory cells in the joint space, resulting in severe pain, joint deformation, and loss of function. It is a feature. For this reason, the principle of arthritis treatment used in the clinic aims to suppress pain and inflammation and minimize loss of joint function. Non-steroidal (NSAIDs) anti-inflammatory drugs such as aspirin and low-dose oral steroidal immunosuppressants such as methotrexate and imran are used as primary drug treatments for arthritis. I have an injection.
しかしながら、これらの薬剤は優れた消炎効能を有していることが知られていて臨床における応用頻度は高いものの、激しい副作用により使用が制限的にならざるを得ない(van Ede et al., Semin. Arthritis Rheum., 27:277, 1998; Peng S & Duggan, Expert. Opin. Drug Saf., 4:157, 2005)。このため、関節炎を効果的に治療するための医学的な関心と研究は依然として持続されており、優れた治療効果を持つ新薬の開発に膨大な予算が費やされているのが現状である。 However, although these drugs are known to have excellent anti-inflammatory effects and are frequently used in clinical practice, their use must be limited due to severe side effects (van Ede et al., Semin Arthritis Rheum., 27: 277, 1998; Peng S & Duggan, Expert. Opin. Drug Saf., 4: 157, 2005). For this reason, medical interest and research for effectively treating arthritis are still ongoing, and a huge budget is being spent on the development of new drugs with excellent therapeutic effects.
上記の如き副作用を解消するために、現在、天然物を用いた関節炎の治療法及び治療剤が開発されて、臨床において活発に適用されている(Darshan & Doreswamy, Phytother. Res., 18:343, 2004)。一部の天然物及びその抽出物を用いた治療剤は強力な消炎効果を示すことが立証されており、副作用が少ないために極めて安全であるというメリットを有する。 In order to eliminate the above-mentioned side effects, arthritis treatments and therapeutic agents using natural products have been developed and applied actively in the clinic (Darshan & Doreswamy, Phytother. Res., 18: 343). , 2004). The therapeutic agents using some natural products and extracts thereof have been proven to have a strong anti-inflammatory effect and have the advantage of being extremely safe due to few side effects.
一方、白花蛇舌草はアカネ科に属するハシカグサ(Hedyotis lindleyanna var. hirsuta HARA or Oldenlandia diffusa L. ROXB.)の一年生植物であって、背は20〜40cmであり、下の部分が横に伸びながら枝が分かれて斜めに立ち、多細胞よりなる白い毛がややある(Yoshida. Y. et al., Int. J. Immunopharmacol., 19:359, 1997)。白花蛇舌草の気味は冷たいものの、毒がなく、味が甘くて苦く、作用する経絡は経胃、経大腸、経小腸などであり、本草学的に清熱解毒、利水通淋、活血化淤(activate blood circulation against stasis)、消癰の効能があって肺熱咳、扁桃腺炎、咽喉炎、蟲垂炎、痢疾、黄疸、子宮付属器炎、関節炎などの各種の炎症及び消化器癌、肝癌、肺癌、リンパ癌及び咽喉癌など各種の癌に活用されている(Tong, I.H. et al., Phytochemistry, 25:1988, 1986)。 On the other hand, the white flower serpentine grass is an annual plant (Hedyotis lindleyanna var. Hirsuta HARA or Oldenlandia diffusa L. ROXB.) That belongs to the Rubiaceae family. The branches are split and stand diagonally, with some white hair consisting of many cells (Yoshida. Y. et al., Int. J. Immunopharmacol., 19: 359, 1997). White flower serpentine grass is cold, but not poisonous, sweet and bitter, and the meridians that act are transgastric, trans large intestine, trans small intestine, etc. active blood circulation against stasis), various inflammations such as lung fever cough, tonsillitis, sore throat, appendicitis, diarrhea, jaundice, adnexitis, arthritis, digestive cancer, liver cancer It is used for various cancers such as lung cancer, lymph cancer and throat cancer (Tong, IH et al., Phytochemistry, 25: 1988, 1986).
また、前記天然物抽出物のうちウルソール酸は種々の植物から抽出されている5環性トリテルペノイド系の化合物であって、関節炎治療における効能及びそのメカニズムが知られている(Miceli, N. et al., J. Ethnopharmacol,, 97:261, 2005; Park et al., Phytother. Res., 18:930, 2004)。 Of the natural product extracts, ursolic acid is a pentacyclic triterpenoid compound extracted from various plants, and its efficacy and mechanism in treating arthritis are known (Miceli, N. et al. ., J. Ethnopharmacol ,, 97: 261, 2005; Park et al., Phytother. Res., 18: 930, 2004).
患部の痛みと炎症を抑制して関節の機能消失を極力抑えることを目指す既存の関節炎治療薬剤は優れた消炎効能を有しているが、胃腸管系の疾患誘発などの深刻な副作用があるという問題点がある。また、天然物を用いた関節炎の治療法及び治療剤は従来の関節炎治療薬剤に比べて消炎効果に劣っているという問題がある。このため、当分野においては人体に安全で且つ効果に優れている消炎効果及び鎮痛用の組成物の開発が切望されているのが現状である。 Existing anti-arthritis drugs aiming to minimize the loss of joint function by suppressing pain and inflammation in the affected area have excellent anti-inflammatory properties, but have serious side effects such as induction of diseases of the gastrointestinal tract There is a problem. In addition, there is a problem that arthritis treatments and therapeutic agents using natural products are inferior in anti-inflammatory effect compared to conventional arthritis therapeutic agents. For this reason, in the present field, the development of an anti-inflammatory and analgesic composition that is safe and effective for the human body is eagerly desired.
そこで、本発明者らは、消炎効果及び鎮痛効果に優れた効果があり、胃腸管系の疾患誘発などの副作用の危険性がない消炎及び鎮痛抑制用の組成物を開発するために鋭意努力した結果、天然物質である白花蛇舌草から抽出したウルソール酸及びオレアノール酸を含有する組成物が消炎及び鎮痛効果があることを確認し、本発明を完成するに至った。 Therefore, the present inventors have made an intensive effort to develop a composition for suppressing inflammation and analgesia, which has an excellent anti-inflammatory effect and analgesic effect, and has no risk of side effects such as induction of diseases of the gastrointestinal tract. As a result, it was confirmed that a composition containing ursolic acid and oleanolic acid extracted from natural white serpentine grass has anti-inflammatory and analgesic effects, and the present invention has been completed.
《技術的課題》
本発明は、一つの観点において、ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物を含む消炎用または鎮痛用の医薬組成物に関する。
《Technical issues》
In one aspect, the present invention relates to an anti-inflammatory or analgesic pharmaceutical composition comprising a purified white flower serpentine extract containing ursolic acid and oleanolic acid.
本発明は、他の観点において、ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物及び食品学的に許容可能な食品添加剤を含む消炎用または鎮痛用の健康機能性食品に関する。 In another aspect, the present invention relates to an anti-inflammatory or analgesic health functional food containing a purified extract of white flower serpentine grass containing ursolic acid and oleanolic acid and a food additive that is foodically acceptable.
本発明は、さらに他の観点において、(a)白花蛇舌草を破砕した後、低級アルコール、水、低級有機酸、低級アルコールエステル、低級ケトン、ハロゲン化炭化水素及びこれらの混合物よりなる群から選ばれる溶媒により抽出した後、濃縮するステップと、(b)前記得られた濃縮物に同量のエチルアセテートを添加した後、2回分画した後に濃縮するステップと、(c)前記得られた濃縮物にエチルアセテート:アセトン:水を4.25〜4.75:4.25〜4.75:0.5〜1.5の割合にて添加して、30〜60℃の条件において溶解させた後、1〜6℃において保管して沈殿物を生成するステップと、(d)前記沈殿物からウルソール酸及びオレアノール酸を含有する抽出精製物を回収するステップと、を含むウルソール酸及びオレアノール酸を含有する消炎用または鎮痛用の白花蛇舌草抽出精製物の製造方法に関する。 In yet another aspect, the present invention provides (a) after crushing white serpentine grass, and then from the group consisting of lower alcohol, water, lower organic acid, lower alcohol ester, lower ketone, halogenated hydrocarbon, and mixtures thereof. Extracting with a selected solvent and concentrating; and (b) adding the same amount of ethyl acetate to the obtained concentrate, then concentrating after fractionating twice, and (c) obtaining the obtained Ethyl acetate: acetone: water was added to the concentrate at a ratio of 4.25 to 4.75: 4.25 to 4.75: 0.5 to 1.5 and dissolved at 30 to 60 ° C. Then, storing at 1 to 6 ° C. to form a precipitate, and (d) recovering an extract purified product containing ursolic acid and oleanolic acid from the precipitate, and ursolic acid and The method of manufacturing a antiinflammatory or blossom Hebishita grass purified extract of analgesic containing oleanolic acid.
本発明の他の特徴及び具現例は、下記の詳細な説明及び特許請求の範囲からなお一層明らかになる。 Other features and implementations of the invention will become even more apparent from the following detailed description and claims.
本発明による白花蛇舌草抽出精製物は、次の段階を経て製造することができる:(a)白花蛇舌草を破砕した後、低級アルコール、水、低級有機酸、低級アルコールエステル、低級ケトン、ハロゲン化炭化水素及びこれらの混合物よりなる群から選ばれる溶媒により抽出した後、濃縮するステップと、(b)前記得られた濃縮物に同量のエチルアセテートを添加した後、2回分画させた後に濃縮するステップと、(c)前記得られた濃縮物にエチルアセテート:アセトン:水を4.25〜4.75:4.25〜4.75:0.5〜1.5の割合にて添加して、30〜60℃の条件において溶解させた後、1〜6℃において保管して沈殿物を生成するステップと、(d)前記沈殿物からウルソール酸及びオレアノール酸含有抽出精製物を回収するステップ。 The white flower serpentine extract and purified product according to the present invention can be produced through the following steps: (a) After crushing white flower serpentine grass, lower alcohol, water, lower organic acid, lower alcohol ester, lower ketone Extracting with a solvent selected from the group consisting of a halogenated hydrocarbon and a mixture thereof, and then concentrating; and (b) adding the same amount of ethyl acetate to the obtained concentrate, followed by fractionating twice. And (c) adding ethyl acetate: acetone: water to the concentrate obtained in a ratio of 4.25 to 4.75: 4.25 to 4.75: 0.5 to 1.5. And adding at a temperature of 30 to 60 ° C., storing at 1 to 6 ° C. to form a precipitate, and (d) purifying an extract containing ursolic acid and oleanolic acid from the precipitate. Collect Step.
前記低級アルコールはメタノール、エタノール、プロパノール、ブタノールなどを使用することができ、前記低級有機酸は酢酸、プロピオン酸、コハク酸及びアジピン酸などを使用することができる。また、前記低級アルコールエステルは、メチルアセテート、エチルアセテートなどを使用することができ、前記低級ケトンは、アセトン、メチルエチルケトンなどを使用することができる。本発明による前記抽出溶媒としては、80%メタノール水溶液または水を使用することが最も好ましい。 As the lower alcohol, methanol, ethanol, propanol, butanol and the like can be used, and as the lower organic acid, acetic acid, propionic acid, succinic acid, adipic acid and the like can be used. The lower alcohol ester may be methyl acetate or ethyl acetate, and the lower ketone may be acetone or methyl ethyl ketone. As the extraction solvent according to the present invention, it is most preferable to use an 80% aqueous methanol solution or water.
本発明による白花蛇舌草抽出精製物の製造方法は、白花蛇舌草から消炎または鎮痛効果に優れた化合物を簡単な方法により高収率にて得ることができるという特徴がある。 The method for producing a purified extract of white flower serpentine according to the present invention is characterized in that a compound excellent in anti-inflammatory or analgesic effect can be obtained from white flower serpentine in a high yield by a simple method.
本発明による白花蛇舌草抽出精製物は、ザイモサンから誘導された空気嚢急性炎症モデル及びフロイントアジュバントを用いた慢性関節炎実験動物モデルにおいて消炎及び鎮痛効果を示している。ザイモサンから誘導する空気嚢炎症モデルは関節炎患者において示す種々の炎症反応に類似する病理学的な症状を示すことにより、関節炎に対する効能評価及びこれと関連するメカニズム研究に汎用されている。本発明者らは、本発明において空気嚢実験を先行して行い、白花蛇舌草抽出精製物の消炎効能を様々な投与容量により検証した。その結果、25mg/kgのドーズ処置群から、空気嚢内白血球遊走を効果的に抑制し、50mg/kgの投与容量において最大の消炎効能を観察することができた。また、50mg/kgの投与容量においては炎症反応により増加すると知られている空気嚢内滲出物のPGE2濃度を効果的に抑制していた。 The extract of purified white flower serpentine according to the present invention exhibits anti-inflammatory and analgesic effects in an air sac acute inflammation model derived from zymosan and a chronic arthritis experimental animal model using Freund's adjuvant. The air sac inflammation model derived from zymosan has been widely used for the evaluation of efficacy against arthritis and related mechanism research by showing pathological symptoms similar to various inflammatory reactions shown in arthritic patients. The present inventors conducted an air sac experiment in advance in the present invention, and verified the anti-inflammatory effect of the white flower serpentine extract and purified product with various doses. As a result, from the 25 mg / kg dose treatment group, leukocyte migration in the air sac was effectively suppressed, and the maximum anti-inflammatory effect could be observed at a dose of 50 mg / kg. In addition, the PGE 2 concentration of exudates in the air sac, which is known to increase due to an inflammatory reaction, was effectively suppressed at a dose of 50 mg / kg.
慢性関節炎実験において本発明による組成物の投与は陽性対照群として使用されたイブプロフェンと同じ度合いの消炎及び鎮痛効能を示すことが観察された。特に、X線映像分析の結果、新生骨増殖抑制効果は極めて卓越しており、物理的な刺激及び熱刺激に対する温熱性痛覚過敏においても優れた鎮痛効果を示すことを観察することができた。また、末梢疼痛時に脊髄において発現されるFosタンパク質含有神経細胞の数も陰性対照群(賦形剤)に比べて急激に減少することが分かる。特に、慢性関節炎群において増加するプラズマ内PGE2の濃度は本発明の白花蛇舌草抽出精製物により陽性対照群であるイブプロフェン処置群と同じレベルに抑制されていた。 In chronic arthritis experiments, it was observed that administration of the composition according to the present invention showed the same degree of anti-inflammatory and analgesic efficacy as ibuprofen used as a positive control group. In particular, as a result of X-ray image analysis, it was observed that the new bone growth inhibitory effect was extremely excellent, and that it showed an excellent analgesic effect even in thermal hyperalgesia to physical and thermal stimuli. It can also be seen that the number of Fos protein-containing neurons expressed in the spinal cord during peripheral pain also decreases sharply compared to the negative control group (excipient). In particular, the concentration of PGE 2 in plasma that increased in the chronic arthritis group was suppressed to the same level as that of the ibuprofen treatment group, which was a positive control group, by the purified white flower serpentine extract of the present invention.
また、本発明の組成物が治療剤として使用可能であるか否かを判断するために、生理及び副作用に関する実験を行った。その結果、本発明によるウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物の投与は、イブプロフェンとは異なり、体重増体率の減少、飼料摂取率の減少及び消化吸収障害がないことを観察することができた。また、胃損傷実験においてウルソール酸及びオレアノール酸群は胃損傷の度合いが賦形剤群と統計的に差が出なかったのに対し、イブプロフェン群においては胃粘膜の損傷が対照群に比べて大幅に増加することが分かる。 In addition, in order to determine whether or not the composition of the present invention can be used as a therapeutic agent, experiments on physiology and side effects were conducted. As a result, the administration of the purified extract of white flower serpentine grass containing ursolic acid and oleanolic acid according to the present invention is different from ibuprofen in that there is no decrease in body weight gain rate, decrease in feed intake rate, and digestive absorption disorder. I was able to observe. In the gastric damage experiment, the ursolic acid and oleanolic acid groups did not show a statistically different degree of gastric damage from the excipient group, whereas the ibuprofen group showed significant damage to the gastric mucosa compared to the control group. It can be seen that it increases.
前記の如き結果をまとめてみると、本発明によるウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物はNSAID系の薬物であるイブプロフェンと同じ効能を示しつつも、胃腸管系の副作用が大幅に減少されて、一次的な安全性に優れていることが分かる。 Summarizing the above results, the white serpentine extract-purified product containing ursolic acid and oleanolic acid according to the present invention has the same effect as ibuprofen, a NSAID drug, but has side effects on the gastrointestinal tract. It can be seen that the primary safety is greatly reduced.
このため、本発明は、ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物を含む消炎用または鎮痛用の医薬組成物を提供する。 Therefore, the present invention provides an anti-inflammatory or analgesic pharmaceutical composition comprising a white flower serpentine extract-purified product containing ursolic acid and oleanolic acid.
本発明による消炎用または鎮痛用の医薬組成物において、前記白花蛇舌草抽出精製物のウルソール酸及びオレアノール酸の含量は80〜95重量%であることを特徴とし、前記ウルソール酸:オレアノール酸の割合は1:0.05〜0.6であることを特徴とする。前記含量比を有する白花蛇舌草抽出精製物はウルソール酸またはオレアノール酸を単独にて用いたものよりも消炎または鎮痛においてなお一層優れた効果を示し、これはウルソール酸とオレアノール酸が共同で作用することにより示す相乗効果によるものであると認められる。 In the anti-inflammatory or analgesic pharmaceutical composition according to the present invention, the ursolic acid and oleanolic acid content of the purified white serpentine grass extract is 80 to 95% by weight, and the ursolic acid: oleanolic acid is used. The ratio is 1: 0.05 to 0.6. A white flower serpentine extract and purified product having the above-mentioned content ratio shows an even better effect in anti-inflammatory or analgesia than those using ursolic acid or oleanolic acid alone, and this is because ursolic acid and oleanolic acid work together It is recognized that this is due to the synergistic effect shown.
本発明による前記医薬組成物は、カバノアナタケ、メシマコブ、カワラタケ、冬虫夏草(Paecilomyces japonica)、サナギタケ(Cordyceps Militaris)、ヤマブシタケ、茯苓、アガリクス、ベッコウタケ、マイタケ、猪苓、ツリガネタケ(Fomes fomentarius)、ヒラタケ、エノキタケ、シイタケ、ヒメマツタケ、ナラタケ、アイタケ、マツタケ及びキクラゲ抽出精製物よりなる群から選ばれた1種以上の生薬材抽出精製物をさらに含有することができ、抗ヒスタミン剤、消炎鎮痛剤、抗癌剤、抗生剤よりなる群から選ばれるいずれか1種以上の薬剤と一緒に製剤化されたことができる。 The pharmaceutical composition according to the present invention includes birch, bamboo shoots, bamboo shoots, Paecilomyces japonica, cordyceps Militaris, yamabushitake, salmon, agaricus, bekkotake, maitake, moth, aritake ment, It can further contain one or more herbal extracts extracted from the group consisting of shiitake, himematsutake, narake, agaric, matsutake, and fungus extract, and consists of an antihistamine, anti-inflammatory agent, anticancer agent, and antibiotic. It can be formulated together with any one or more drugs selected from the group.
本発明の抗ヒスタミン剤はアレルギー疾患の1つの原因であるヒスタミンの作用に拮抗する薬剤であって、本発明の組成物によりアレルギー疾患を誘発しうる可能性を封鎖することが可能になり、消炎鎮痛剤は炎症を鎮静する薬をいい、本発明の組成物に前記消炎鎮痛剤をさらに添加する場合、消炎効果を極大化することができる。また、前記抗癌剤は悪性腫瘍の治療のために使用される化学療法剤を総称するものであり、前記抗生剤は微生物が生産する代謝産物により少量で他の微生物の発育を抑制したり死滅させる物質を言う。本発明の組成物に前記物質をさらに添加する場合、本発明の消炎または鎮痛効果の他に抗アレルギー効果、抗癌効果などの効果を期待することができる。 The antihistamine of the present invention is a drug that antagonizes the action of histamine, which is one cause of allergic diseases, and the composition of the present invention makes it possible to block the possibility of inducing allergic diseases. Refers to a drug for sedating inflammation, and when the anti-inflammatory analgesic is further added to the composition of the present invention, the anti-inflammatory effect can be maximized. The anticancer agent is a general term for chemotherapeutic agents used for the treatment of malignant tumors, and the antibiotic is a substance that suppresses or kills the growth of other microorganisms in a small amount by a metabolite produced by the microorganism. Say. When the substance is further added to the composition of the present invention, effects such as an antiallergic effect and an anticancer effect can be expected in addition to the anti-inflammatory or analgesic effect of the present invention.
本発明の組成物の薬学的な投与形態は、これらの薬学的に許容可能な塩の形でも使用でき、また、単独にて使用でき、または、他の薬学的な活性化合物と結合して使用できるだけではなく、適当な集合として使用できる。 The pharmaceutical dosage forms of the compositions of the invention can be used in the form of their pharmaceutically acceptable salts, or can be used alone or in combination with other pharmaceutically active compounds. Not only can it be used as a suitable set.
本発明による消炎及び鎮痛用の医薬組成物は、それぞれ通常の方法により散剤、顆粒剤、錠剤、カプセル剤、懸濁液、エマルジョン、シロップ、エアロゾルなどの経口型剤型、外用剤、座剤及び滅菌注射溶液の形に剤型化して使用可能である。本発明の消炎及び鎮痛用の組成物を含む組成物に含まれうる担体、賦形剤及び希釈剤としては、ラクトース、デキストロース、スクロース、ソルビトール、マンニトール、キシリトール、エリスリトール、マルチトール、澱粉、アカシアゴム、アルジネート、ゼラチン、カルシウムフォスフェート、カルシウムシリケート、セルロース、メチルセルロース、未晶質セルロース、ポリビニールピロリドン、水、メチルヒドロキシベンゾエート、プロピルヒドロキシベンゾエート、タルク、マグネシウムステアレート及び鉱物油が挙げられる。製剤化する場合には、通常使用する充填剤、増量剤、結合剤、湿潤剤、崩解剤、界面活性剤などの希釈剤または賦形剤を用いて調製可能である。経口投与のための固形製剤としては、錠剤、丸剤、散剤、顆粒剤、カプセル剤などが含まれ、このような固形製剤は前記セフテゾールに少なくとも1種以上の賦形剤、例えば、澱粉、カルシウムカーボネート、スクロースまたはラクトース、ゼラチンなどを混ぜて調製することができる。また、単なる賦形剤の他に、マグネシウムステアレート、タルクなどの潤滑剤も使用される。経口のための液状製剤としては、懸濁剤、耐溶液剤、乳剤、シロップ剤などが挙げられるが、頻繁に使用される単純希釈剤である水、液状パラフィンの他に、種々の賦形剤、例えば、湿潤剤、甘味剤、芳香剤、保存剤などが含まれうる。非経口投与のための製剤には滅菌された水溶液、非水性溶剤、懸濁剤、乳剤、凍結乾燥製剤、座剤が含まれる。非水性溶剤、懸濁剤としてはプロピレングリコール、ポリエチレングリコール、オリーブ油などの植物性油、エチルオレートなどの注射可能なエステルなどが使用可能である。座剤の基剤としては、ウィテプソール、マクロゴール、ツイーン61、カカオ脂、ラウリン脂、グリセロゼラチンなどが使用可能である。 The anti-inflammatory and analgesic pharmaceutical compositions according to the present invention are prepared by oral methods such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and It can be used in the form of a sterile injection solution. Carriers, excipients and diluents that can be included in the composition containing anti-inflammatory and analgesic composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum , Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, amorphous cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulating, it can be prepared using diluents or excipients such as fillers, fillers, binders, wetting agents, disintegrating agents, surfactants and the like that are usually used. Examples of solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one or more excipients such as starch, calcium, etc. It can be prepared by mixing carbonate, sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solution-resistant agents, emulsions, syrups, etc., but various excipients in addition to water and liquid paraffin, which are frequently used simple diluents. For example, wetting agents, sweeteners, fragrances, preservatives and the like can be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories. As non-aqueous solvents and suspending agents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate can be used. As a suppository base, witepsol, macrogol, Tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
本発明の組成物の好適な投与量は、患者の状態及び体重、疾病の度合い、薬物の形態、投与経路及び期間によって異なるが、当業者により適切に選択可能である。しかしながら、好適な効果のために、本発明の組成物は0.0001〜100mg/kg/dayにて、好ましくは、0.001〜100mg/kg/dayにて投与した方が良い。投与は、1日につき1回投与してもよく、数回に分けて投与してもよい。前記投与量はいずれにせよ本発明の範囲を限定するものではない。 A suitable dose of the composition of the present invention varies depending on the condition and weight of the patient, the degree of disease, the form of the drug, the administration route and the period, but can be appropriately selected by those skilled in the art. However, for a suitable effect, the composition of the present invention should be administered at 0.0001 to 100 mg / kg / day, preferably at 0.001 to 100 mg / kg / day. Administration may be performed once per day, or may be divided into several times. The dosage does not limit the scope of the present invention in any way.
本発明の消炎用及び鎮痛用の組成物は、ラット、マウス、家畜、人間などの哺乳動物に様々な経路を通じて投与可能である。投与のあらゆる方式は予想可能であるが、例えば、経口、直腸または静脈、筋肉、皮下、子宮内硬膜または脳血管内注射により投与可能である。 The anti-inflammatory and analgesic composition of the present invention can be administered to mammals such as rats, mice, domestic animals and humans through various routes. Any mode of administration is predictable, but can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura or intracranial injection.
本発明は他の観点において、ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物及び食品学的に許容可能な食品添加剤を含む消炎用または鎮痛用の健康機能性食品を提供する。 In another aspect, the present invention provides an anti-inflammatory or analgesic health functional food containing a purified extract of white flower serpentine grass containing ursolic acid and oleanolic acid and a food additive that is pharmaceutically acceptable.
本発明による消炎用または鎮痛用の健康機能性食品において、前記白花蛇舌草抽出精製物のウルソール酸及びオレアノール酸の含量は80〜95重量%であることを特徴とし、前記ウルソール酸:オレアノール酸の割合は1:0.05〜0.6であることを特徴とする。 In the anti-inflammatory or analgesic health functional food according to the present invention, the ursolic acid and oleanolic acid content of the purified white serpentine grass extract is 80 to 95% by weight, and the ursolic acid: oleanolic acid is used. The ratio is 1: 0.05 to 0.6.
本発明による健康機能性食品は、カバノアナタケ、メシマコブ、カワラタケ、冬虫夏草、サナギタケ、ヤマブシタケ、茯苓、アガリクス、ベッコウタケ、マイタケ、猪苓、ツリガネタケ、ヒラタケ、エノキタケ、シイタケ、ヒメマツタケ、ナラタケ、アイタケ、マツタケ及びキクラゲ抽出精製物よりなる群から選ばれた1種以上の生薬材抽出精製物をさらに含有することを特徴とする。 The health functional foods according to the present invention include birch, bamboo shoots, bamboo shoots, cordyceps, sanagitake, yamabushitake, bamboo shoots, agaricus, bekko mushrooms, maitake, bamboo shoots, mushrooms, oyster mushrooms, shiitake mushrooms, matsutake mushrooms, It is characterized by further containing one or more kinds of herbal extracts extracted and purified selected from the group consisting of purified products.
本発明の消炎用または鎮痛用の組成物は、機能性食品及び健康補助食品の製造時に食品の主成分または添加剤及び補助剤として使用可能である。 The anti-inflammatory or analgesic composition of the present invention can be used as a main component of food or an additive and auxiliary agent in the production of functional foods and health supplements.
この明細書において、「機能性食品」とは、一般食品に本発明の組成物を添加することにより一般食品の機能性を高めた食品を意味する。機能性は物性及び生理機能性に大別できるが、本発明の組成物を一般食品に添加する場合、一般食品の物性及び生理機能性が向上され、本発明はこのような向上した機能の食品を包括して「機能性食品」と定義する。 In this specification, the “functional food” means a food whose functionality is improved by adding the composition of the present invention to the general food. Functionality can be broadly classified into physical properties and physiological functions. When the composition of the present invention is added to general foods, the physical properties and physiological functions of general foods are improved. Is defined as “functional food”.
例えば、本発明の組成物の消炎または鎮痛機能を用いて消炎用または鎮痛用の健康機能性食品を製造することができ、機能性強化食品、癌予防飲料などを製造することができるのである。なお、本発明の組成物は関節炎患者のための食餌療法または健康補助食品(dietary supplement)の製造にも応用可能である。 For example, the anti-inflammatory or analgesic health functional food can be produced by using the anti-inflammatory or analgesic function of the composition of the present invention, and a functionally enhanced food, a cancer prevention beverage, and the like can be produced. Note that the composition of the present invention can also be applied to the production of dietary therapy or dietary supplements for arthritic patients.
上記の他に、本発明の組成物は種々の栄養剤、ビタミン、鉱物(電解質)、合成風味剤及び天然風味剤などの風味剤、着色剤及び充填剤(チーズ、チョコレートなど)、ペクチン酸及びその塩、アルギン酸及びその塩、有機酸、保護性コロイド増粘剤、pH調節剤、安定化剤、防腐剤、グリセリン、アルコール、炭酸飲料に使用される炭酸化剤などの食品添加剤を含有することができる。これらのほかに、本発明の組成物は天然果物ジュース飲料及び野菜飲料の製造のための果肉を含有することができる。これらの成分は独立してまたは組み合わせて使用することができる。これらの添加剤の割合はあまり重要ではないが、本発明の消炎及び鎮痛のための組成物100重量部当たりに0.01〜20重量部の範囲において選択されることが一般的である。 In addition to the above, the composition of the present invention comprises various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and fillers (cheese, chocolate, etc.), pectinic acid and Contains food additives such as its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonates used in carbonated beverages be able to. In addition to these, the compositions of the present invention can contain pulp for the production of natural fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of these additives is not critical, but is generally selected in the range of 0.01 to 20 parts by weight per 100 parts by weight of the anti-inflammatory and analgesic composition of the present invention.
以下、実施例を挙げて本発明をより詳細に説明する。但し、これらの実施例は単に本発明を一層詳しく説明するためのものであり、本発明の要旨により本発明の範囲がこれらの実施例に限定されるものではないということは、当分野における通常の知識を有する者にとって明らかである。 Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are merely for explaining the present invention in more detail, and it is usual in the art that the scope of the present invention is not limited to these examples by the gist of the present invention. It is clear to those who have knowledge of.
実施例1:ウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物(OE)の製造
白花蛇舌草1kgに10倍の80%メタノール(MeOH)水溶液を添加して常温において24時間かけて2回抽出した。前記抽出液を真空濃縮器において20倍濃縮した後、同量のエチルアセテートを添加して2回分画を繰り返し行った。エチルアセテート分画物を最大に濃縮した後、40〜50℃の条件において、濃縮物にエチルアセテート:アセトン:水=4.5:4.5:1の溶液を添加して溶解させた後、低温(4℃)において保管して沈殿を確認した。遠心分離してウルソール酸及びオレアノール酸が含有された白花蛇舌草抽出精製物(OE)(純度:89.9%、ウルソール酸:オレアノール酸=1:0.37)を得た。
Example 1: Manufacture of purified extract of white flower serpentine grass (OE) containing ursolic acid and oleanolic acid 10 kg of 80% methanol (MeOH) solution was added to 1 kg of white flower serpentine grass over 24 hours at room temperature. Extracted twice. The extract was concentrated 20 times in a vacuum concentrator, the same amount of ethyl acetate was added, and fractionation was repeated twice. After maximally concentrating the ethyl acetate fraction, the solution was dissolved by adding a solution of ethyl acetate: acetone: water = 4.5: 4.5: 1 to the concentrate at 40 to 50 ° C. Precipitation was confirmed by storage at a low temperature (4 ° C.). Centrifugation gave a white serpentine grass extract and purified product (OE) containing ursolic acid and oleanolic acid (purity: 89.9%, ursolic acid: oleanolic acid = 1: 0.37).
前記ウルソール酸及びオレアノール酸が含有された白花蛇舌草抽出精製物をHPLCにより分析した。分析条件は検出器206nmにおいて移動床アセトニトリル:水(1.25%のH3PO4中において)=86:14、流速0.5mL/min、カラムはフェノメネックスLunaC18、250*4.60mmである。図1は、本発明による白花蛇舌草抽出精製物のHPLC分析結果を示すものであり、白花蛇舌草抽出精製物2mgを秤量して100%メタノール1mLを添加溶解して分析したものである。 The purified white flower serpentine grass extract containing ursolic acid and oleanolic acid was analyzed by HPLC. The analysis conditions are moving bed acetonitrile: water (in 1.25% H 3 PO 4 ) = 86: 14 at a detector 206 nm = 86: 14, flow rate 0.5 mL / min, column is Phenomenex Luna C18, 250 * 4.60 mm. is there. FIG. 1 shows the results of HPLC analysis of a white flower serpentine extract and purified product according to the present invention. 2 mg of white flower serpentine extract and purified product are weighed and analyzed by adding 1 mL of 100% methanol. .
HPLCの分析結果、15.95分及び16.3833分にそれぞれオレアノール酸及びウルソール酸のピークが現れた。 As a result of HPLC analysis, peaks of oleanolic acid and ursolic acid appeared at 15.95 minutes and 16.3833 minutes, respectively.
実施例2:空気嚢急性炎症実験動物モデルにおける消炎及び鎮痛効能
2−1:実験動物モデルの準備
空気嚢モデルを用いた消炎効能検証のために、ICRマウス(25g、ハンリム実験動物)を使用し、12時間おきに光の明暗調節を行い、温度と湿度を一定に維持し、飼料と水は頻繁に供給した。前記マウスに急性炎症を誘発するために、マウスの背に空気嚢を作って人為的な独立空間を形成した後、0.1%ザイモサン(酵母細胞壁)を500μL容量にて注射して急性炎症を誘発した。
Example 2: Anti-inflammatory and analgesic efficacy in air sac acute inflammation experimental animal model 2-1: Preparation of experimental animal model For verification of anti-inflammatory effect using air sac model, ICR mice (25 g, Hanrim experimental animal) were used. The light intensity was adjusted every 12 hours, the temperature and humidity were kept constant, and feed and water were frequently supplied. In order to induce acute inflammation in the mouse, an air sac is formed on the back of the mouse to form an artificial independent space, and then 0.1% zymosan (yeast cell wall) is injected in a volume of 500 μL to induce acute inflammation. Triggered.
2−2:消炎効能の評価
(1)空気嚢に遊走された白血球数の評価
ICRマウス(25g、ハンリム実験動物)70匹を選抜して、下記表1に記載の薬剤を投与した。10匹は賦形剤のみを投与し、10匹はイブプロフェンを投与し、残りの50匹(12.5mg/kg、25mg/kg、50mg/kg、100mg/kg、200mg/kg;それぞれ10匹)は実施例1において製造されたウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物(OE)を投与した。
2-2: Evaluation of anti-inflammatory effect (1) Evaluation of the number of leukocytes migrating to the air sac 70 ICR mice (25 g, Hanrim experimental animal) were selected and administered with the drugs listed in Table 1 below. 10 animals received vehicle only, 10 animals received ibuprofen and the remaining 50 animals (12.5 mg / kg, 25 mg / kg, 50 mg / kg, 100 mg / kg, 200 mg / kg; 10 animals each) Was administered with the white serpentine grass extract purified product (OE) containing ursolic acid and oleanolic acid prepared in Example 1.
前記と同量の賦形剤、イブプロフェン、白花蛇舌草抽出精製物(OE)をゾンデを用いて50μL/10gの容量にて投与し、前記薬剤を投与してから1時間経過後、空気嚢を作って人為的な独立空間を形成した後、0.1%ザイモサン(酵母細胞壁)を500μLの容量にて注射して急性炎症を誘発させた。急性炎症を誘発した後、嚢内の滲出液を採取して、遊走した白血球数を測定して炎症の指標として分析した(図2)。その結果、図2に示すように、本発明の白花蛇舌草抽出精製物(OE)を用いた消炎効能評価実験の結果、白花蛇舌草抽出精製物(OE)25mg/kgから賦形剤対照群に比べて炎症性細胞の空気嚢内遊走を抑制することが観察され、優れた消炎効能を観察することができた。特に、本発明の白花蛇舌草抽出精製物(OE)50mg/kgにおいて最大の消炎効能を示し、この効能は薬物対照群であるイブプロフェン処置(100mg/kg)において観察される消炎効能に類似していた。 The same amount of excipient, ibuprofen, and white flower serpentine extract (OE) were administered in a volume of 50 μL / 10 g using a sonde, and 1 hour after the administration of the drug, After forming an artificially independent space, 0.1% zymosan (yeast cell wall) was injected in a volume of 500 μL to induce acute inflammation. After inducing acute inflammation, exudates in the sac were collected and the number of leukocytes migrated was measured and analyzed as an index of inflammation (FIG. 2). As a result, as shown in FIG. 2, as a result of the anti-inflammatory effect evaluation experiment using the white flower serpentine extract purified product (OE) of the present invention, the white flower serpentine grass extract purified product (OE) 25 mg / kg was used as an excipient. Compared to the control group, it was observed that the migration of inflammatory cells in the air sac was suppressed, and an excellent anti-inflammatory effect could be observed. In particular, the present invention shows the maximum anti-inflammatory effect at 50 mg / kg of white flower serpentine extract (OE), which is similar to the anti-inflammatory effect observed in the drug control group ibuprofen treatment (100 mg / kg). It was.
(2)空気嚢滲出物におけるPGE2量の測定
賦形剤を投与したマウス10匹と、イブプロフェンを投与したマウス10匹及び本発明の白花蛇舌草抽出精製物(OE)(50mg/kg)を投与したマウス10匹の前記2−2−1から抽出した滲出液を遠心分離した後、上澄液を回収してPGE2の量を測定した(図3)。その結果、図3に示すように、本発明の白花蛇舌草抽出精製物(OE)50mg/kgの経口投与群はイブプロフェンに比べてはPGE2の放出量が多かったが、賦形剤対照群に比べてPGE2の放出量が有意に減少していることを観察することができる。
(2) Measurement of PGE 2 amount in air sac exudates 10 mice administered vehicle, 10 mice administered ibuprofen, and white serpentine grass extract purified product (OE) of the present invention (50 mg / kg) After centrifuging the exudate extracted from the above-mentioned 2-2-1 of 10 mice administered with the supernatant, the supernatant was collected and the amount of PGE 2 was measured (FIG. 3). As a result, as shown in FIG. 3, the oral administration group of white flower serpentine grass extract purified product (OE) 50 mg / kg of the present invention had a higher release amount of PGE 2 than ibuprofen. It can be observed that the amount of PGE 2 released is significantly reduced compared to the group.
前記(1)及び(2)の結果をまとめるとき、本発明の白花蛇舌草抽出精製物(OE)により誘導される消炎効能は急性炎症反応において重要な役割を果たすシクロオキシゲナーゼ活性抑制に起因することを確認することができた。さらに、以下に実施される慢性関節炎実験動物を用いた抗関節炎効能評価実験に50mg/kgの白花蛇舌草抽出精製物(OE)を適用した。 When summarizing the results of the above (1) and (2), the anti-inflammatory effect induced by the purified extract of white flower serpentine grass (OE) of the present invention is due to suppression of cyclooxygenase activity which plays an important role in acute inflammatory reaction I was able to confirm. Furthermore, 50 mg / kg white flower serpentine grass extract purified product (OE) was applied to the anti-arthritis efficacy evaluation experiment using the chronic arthritis experimental animal carried out as follows.
実施例3:慢性関節炎実験動物モデルにおける消炎及び鎮痛効能
3−1:実験動物モデルの準備
慢性関節炎モデルを用いた消炎効能の検証のためには、スプラーグ-ドーリーラット(180g、ソウル大学実験動物研究所)を使用し、12時間おきに光の明暗を調節し、温度と湿度を一定に維持し、飼料と水は自由供給した。
Example 3: Anti-inflammatory and analgesic efficacy in an experimental animal model of chronic arthritis 3-1: Preparation of an experimental animal model For verification of anti-inflammatory efficacy using a chronic arthritis model, Sprague-Dawley rats (180 g, Seoul National University Experimental Animal Research) ), The light intensity was adjusted every 12 hours, the temperature and humidity were kept constant, and feed and water were supplied freely.
スプラーグ-ドーリーラット24匹を選抜して、表2に記載の薬剤を投与した。8匹は賦形剤のみを投与し、8匹はイブプロフェンを投与し、残りの8匹は50mg/kgの本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)を投与した。 Twenty-four Sprague-Dawley rats were selected and administered with the drugs listed in Table 2. 8 animals received vehicle only, 8 animals received ibuprofen, and the remaining 8 animals received white snake tongue extract extract (OE) containing 50 mg / kg of ursolic acid and oleanolic acid of the present invention. did.
前記と同量の賦形剤、イブプロフェン、本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)をゾンデを用いて50μL/10gの容量にて投与した。前記薬剤を投与してから1時間が経過した後、空気嚢を作って人為的な独立空間を形成した後、関節炎を誘発するために準備されたフロイントアジュバント(ミコバクテリウム・ブチリカムをミネラルオイルに20mg/mLの濃度にて浮遊させる)をラットの足裏に50μLずつ注射した。 The same amount of excipient, ibuprofen, ursolic acid and oleanolic acid extract of the present invention (OE) was administered in a volume of 50 μL / 10 g using a sonde. One hour after the administration of the drug, an air sac is formed to form an artificial independent space, and then Freund's adjuvant prepared for inducing arthritis (Mycobacterium butyricum is used as mineral oil). 50 μL each was injected into the sole of the rat.
3−2:消炎評価
薬物は関節炎を誘発した後、12日目から21日目まで投与した。関節炎に対する痛み及び炎症に対する指標として下記に示す項目を測定し、関節炎を誘発する前にベースライン値(day0)を測定した。実験は関節炎誘発21日後に終了した。
3-2: Anti-inflammatory evaluation The drug was administered from the 12th day to the 21st day after inducing arthritis. The following items were measured as indices for pain and inflammation for arthritis, and the baseline value (day 0) was measured before inducing arthritis. The experiment was terminated 21 days after arthritis induction.
(1)足首浮腫測定
フロイントアジュバントを注入して慢性関節炎を誘導した後、約3日が経過してから右足においては1次炎症反応により足首浮腫を観察することができた(図4(A))。関節炎誘発後約12日が経過してからは全身的な免疫反応による2次炎症反応により左足からも足首浮腫が観察された(図4(B))。関節炎誘発12日目から本発明の白花蛇舌草抽出精製物(OE)を経口投与して消炎効能を検証した結果、図4に示すように、本発明の白花蛇舌草抽出精製物(OE)50mg/kg投与群は1次炎症である右足と転移された左足の両方において足首の浮腫を効果的に抑制すると評価された。また、このような本発明の白花蛇舌草抽出精製物(OE)の足首浮腫の抑制効能は薬物対照群であるイブプロフェン投与群と類似する効果を示すことから、極めて優れた消炎効能を有すると評価された。
(1) Measurement of ankle edema After induction of chronic arthritis by injecting Freund's adjuvant, ankle edema could be observed in the right foot due to primary inflammatory reaction after about 3 days (FIG. 4 (A)). ). After about 12 days from the induction of arthritis, ankle edema was also observed from the left foot due to a secondary inflammatory reaction caused by a systemic immune reaction (FIG. 4B). As a result of verifying the anti-inflammatory effect by orally administering the white flower serpentine extract extract (OE) of the present invention from the 12th day after induction of arthritis, as shown in FIG. 4, the white flower serpentine extract extract (OE) of the present invention was obtained. ) The 50 mg / kg administration group was evaluated to effectively suppress ankle edema in both the primary inflammation and the metastasized left foot. Moreover, since the inhibitory effect of the ankle edema of the white flower serpentine grass extract purified product (OE) of the present invention shows an effect similar to that of the ibuprofen administration group which is a drug control group, it has an extremely excellent anti-inflammatory effect. It was evaluated.
図5は、関節炎誘発21日後にマウスの右の足首をX線撮影した写真であり、イブプロフェン100mg/kg投与群(B)と本発明の白花蛇舌草抽出精製物(OE)50mg/kg投与群(C)は足首浮腫抑制能が有意的に高いことが分かる。図6は、前記のように、動物の足部位をX線撮影した後、映像分析を通じて関節炎による軟部組織の腫脹及び新生骨増殖に対する薬物の効果を分析した結果を示すグラフである。 FIG. 5 is an X-ray photograph of the right ankle of the mouse 21 days after induction of arthritis. The ibuprofen 100 mg / kg administration group (B) and the white flower serpentine extract extract (OE) 50 mg / kg of the present invention were administered. It can be seen that the group (C) has a significantly high ability to suppress ankle edema. FIG. 6 is a graph showing the results of analyzing the effect of drugs on soft tissue swelling and new bone growth due to arthritis through X-ray imaging after X-ray imaging of an animal's foot as described above.
その結果、図6に示すように、本発明の白花蛇舌草抽出精製物(OE)を経口投与した実験動物群の右の足首の場合、関節炎により誘発される軟部組織の腫脹及び新生骨増殖が顕著に抑制されることが分かる。また、2次炎症反応により誘発される左足の新生骨増殖も本発明の白花蛇舌草抽出精製物(OE)の投与により減少されることが分かる。特に、本発明の白花蛇舌草抽出精製物(OE)は新生骨増殖に対する効能が極めて卓越しており、薬物対照群であるイブプロフェン処置群において観察される抑制効果に類似していることが分かる。 As a result, as shown in FIG. 6, in the case of the right ankle of the experimental animal group to which the white flower serpentine grass extract purified product (OE) of the present invention was orally administered, soft tissue swelling and new bone growth induced by arthritis It can be seen that is significantly suppressed. In addition, it can be seen that the new bone growth of the left foot induced by the secondary inflammatory reaction is also reduced by the administration of the white flower serpentine extract extract (OE) of the present invention. In particular, the white serpentine grass extract and purified product (OE) of the present invention has an extremely excellent effect on the growth of new bone, and is similar to the inhibitory effect observed in the ibuprofen treatment group, which is a drug control group. .
(2)プラズマ内のPGE2濃度測定
関節炎誘発21日後に各グループにおいて血液を採取してプラズマPGE2の濃度を測定した結果、図7に示すように、陰性対照群(賦形剤)に比べて本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)を投与した群はPGE2濃度が顕著に減少していた。この結果は、陽性対照群であるイブプロフェン処置群において観察される抑制効果に類似しており、このため、本発明の組成物が優れた消炎効能を有していることを再検証することができた。
(2) Measurement of PGE 2 concentration in plasma As a result of collecting blood in each group and measuring the concentration of plasma PGE 2 21 days after arthritis induction, as shown in FIG. In the group to which the white flower serpentine extract extract (OE) containing ursolic acid and oleanolic acid according to the present invention was administered, the PGE 2 concentration was significantly reduced. This result is similar to the inhibitory effect observed in the ibuprofen treatment group, which is a positive control group, and thus it can be re-verified that the composition of the present invention has an excellent anti-inflammatory effect. It was.
3−3:鎮痛評価
(1)機械的しきい値テスト
関節炎が誘発された後、本発明の白花蛇舌草抽出精製物(OE)の投与が機械的・物理的な刺激の敏感度に及ぼす影響を評価した。機械的な刺激に対する痛覚過敏反応は鎮痛効果測定装置(LE7356、ドイツのLETICA社製)を用いて回避反応または痛みの訴え時まで加えられた等級別の機械的な力(g)を5分おきに2回ずつ測定し、測定実験値をもって平均値を適用した(ランダル・セリット法)。正常ラットにおいて機械的な痛覚しきい値は140〜160gであった。実験の結果、白花蛇舌草抽出精製物(OE)の投与群は右足と左足の両方において関節炎誘発後21日が経過してから物理的な刺激により誘導される痛みに優れた鎮痛効果を示していた(図8)。また、図8(A)に示すように、右足の場合、陽性対照薬物であるイブプロフェンよりも優れた鎮痛効果を観察することができた。上記の如き結果をまとめてみると、本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)は、関節炎誘発時に、物理的な刺激による痛みに対して優れた鎮痛効果を有していることが分かる。
3-3: Analgesic evaluation (1) Mechanical threshold test After arthritis is induced, administration of the white serpentine grass extract purified product (OE) of the present invention affects the sensitivity of mechanical and physical stimuli. The impact was evaluated. The hyperalgesic response to mechanical stimuli is determined by using the analgesic effect measuring device (LE7356, manufactured by LETICA, Germany) by the mechanical force (g) according to the grade applied until the avoidance reaction or the pain complaint every 5 minutes. The average value was applied with the measured experimental value (Randal Celit method). The mechanical pain threshold in normal rats was 140-160 g. As a result of the experiment, the administration group of white flower serpentine extract (OE) showed an analgesic effect excellent in pain induced by physical stimulation after 21 days from the induction of arthritis in both the right foot and the left foot. (FIG. 8). In addition, as shown in FIG. 8A, in the case of the right foot, an analgesic effect superior to ibuprofen, which is a positive control drug, could be observed. Summarizing the above results, the white serpentine extract extract (OE) containing ursolic acid and oleanolic acid of the present invention has an excellent analgesic effect on pain caused by physical irritation when arthritis is induced. You can see that
(2)熱しきい値テスト
関節炎が誘発された後、白花蛇舌草抽出精製物(OE)が誘発される熱刺激に対する敏感度に及ぼす影響を評価した。実験動物の熱刺激に対する痛覚過敏を測定するために、ハーグリーブスの方法を用いた(ハーグリーブスら、1988)。ラットをガラス表面の上のプラスチックチャンバー中に5分間ならした後、輻射熱により足裏と接触するガラス表面下に焦点を合わせて刺激を与えた。回避反応を示すのにかかる時間である退避潜在時間(sec)はデジタル時間と連結されている光感受性電池を通じて測定される。光の強度は正常ラットにおいて9〜10秒に回避反応を示すように調節した。実験間隔は5分とし、2回ずつ測定して平均値を適用した。関節炎誘発後の実験結果、陰性対照群(賦形剤)に比べて本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)処置群は右脚と左脚の両方において関節炎時に観察される熱刺激に対する敏感度の増加を大幅に抑制することが観察された(図9)。前記の如き結果から、関節炎により発生する熱刺激敏感症状に対して本発明の白花蛇舌草抽出精製物(OE)は陽性対照群であるイブプロフェンと同じ程度の鎮痛効果があることが分かる。
(2) Thermal threshold test After arthritis was induced, the effect of white serpentine grass extract purified product (OE) on the sensitivity to the induced thermal stimulus was evaluated. The Hargreaves method was used to measure hyperalgesia to thermal stimuli in laboratory animals (Hergreaves et al., 1988). Rats were allowed to sit in a plastic chamber above the glass surface for 5 minutes and then focused and stimulated underneath the glass surface in contact with the sole by radiant heat. The evacuation latent time (sec), which is the time taken to show an avoidance reaction, is measured through a photosensitive cell connected to digital time. The intensity of light was adjusted to show an avoidance response in 9 to 10 seconds in normal rats. The experimental interval was 5 minutes, and the average value was applied after measuring twice. As a result of the experiment after induction of arthritis, the treated group of white serpentine grass extract (OE) containing ursolic acid and oleanolic acid of the present invention compared to the negative control group (vehicle) showed arthritis in both the right and left legs. It was observed that the increase in sensitivity to thermal stimuli sometimes observed was significantly suppressed (FIG. 9). From the results as described above, it can be seen that the white serpentine grass extract and purified product (OE) of the present invention has the same analgesic effect as ibuprofen, which is a positive control group, for heat-sensitive sensitive symptoms caused by arthritis.
(3)脊髄内のFosタンパク質の数的変動検索
本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)の痛みの減少効果を調べるために、痛みに預かる神経細胞であるFosタンパク質の発現の度合いを調べてみた。実験方法は、下記の通りである。実験が終了された後(21日)、脊髄内c−Fosタンパクの免疫組織化学染色のために動物を5%イソフルランにより吸入麻酔させ、心臓を通じてcalcium−free tyrode溶液から灌流した後、ルーナース固定液(4%パラホルムアルデヒド、0.2%ピクリン酸、0.1Mフォスファート緩衝溶液、pH6.9、TPBS)により灌流固定した。灌流後に直ちに脊髄を分離して同じ固定液に4時間かけて後固定した。そして、冷蔵温度において48時間かけて30%スクロース(PBS中のスクロース、pH7.4)により凍結保護を行った。脊髄をサイフォンガスにより急速冷凍した後、クライオスタット(ドイツマイクロム社製)を用いてL3〜L5脊髄部分を40m厚さの切片にした。この後、TPBSにより5分ずつ6回洗浄し、内在性ペルオキシダーゼの活性をなくすために0.3%H2O2/TPBSによりクェンチングし、1%ヤギ血清/0.3%Triton X−100により常温において1時間かけて反応させて非特異的な反応を遮断した(プレブロック過程)。浮遊切片をポリクローナルウサギc−Fos抗体(カルビオケム、1:10、000)と4℃において24時間反応させた後、TPBSにより5分ずつ6回洗浄し、この切片を2次抗体であるgoatanti−RbIgG(ベクトル、1%NGS/Triton X100/TPBS1:200希釈)と常温において1時間かけて反応させた。その後、TPBSにより5分ずつ6回洗浄し、ストレプトアビジン(アビジン−ビオチン反応、0.3%トリトンスX/TPBS1:200希釈液)反応を常温において1時間かけて行った後、TPBSにより5分ずつ6回洗浄した。C−Fosの発現は3−3ジアミノ−ベンジジン(米国シグマケミカルス)反応を通じて検証した。この後、TPBSにより5分ずつ6回洗浄し、組織切片はアルコールを用いて脱水過程を経た後、キシレンにより透明化過程を行った。関節炎が誘発された後、白花蛇舌草抽出精製物(OE)が脊髄内Fosタンパク質発現に及ぼす影響を評価した結果、図10に示すように、陰性対照群(A)に比べて、イブプロフェン(B)及び本発明の白花蛇舌草抽出精製物(OE)投与群(C)においてFosタンパク質が少なく観察されることが分かる。また、図10および図11に示すように、陰性対照群(賦形剤)においては関節炎を一次的に誘発した右足の慢性の痛みによる右側脊髄のFLI(Fos様免疫反応、Fosタンパク質発現性)神経細胞の数及び関節炎の左足への転移を説明する左側脊髄のFLI神経細胞数がそれぞれ浅い層(superficial dorsal horn、SDH)、脊髄固有核(nucleus proprius、NP)、首(neck of dorsal horn、NECK)部位においていずれも急激に増加することが分かる(Kwon et al., Pain, 90:271, 2001; Kwon et al., Life Sciences, 71:191, 2002)。これに対し、本発明の白花蛇舌草抽出精製物(OE)は右側と左側の脊髄の両方においてFLI神経細胞の数が浅い層(SDH)、脊髄固有核(NP)、首(NECK)部位においてほとんど同量減少し、関節炎が誘発された右側よりも左側脊髄のNP部位においてなお一層減少した(図11)。
(3) Numeric variation search of Fos protein in spinal cord In order to examine the pain-reducing effect of white flower serpentine extract (OE) containing ursolic acid and oleanolic acid of the present invention, it is a nerve cell that is put in pain The degree of expression of Fos protein was examined. The experimental method is as follows. After the experiment was completed (day 21), the animals were inhaled by anesthesia with 5% isoflurane for immunohistochemical staining of c-Fos protein in the spinal cord, perfused from calcium-free tyrode solution through the heart, and then Lunar's fixative Perfusion fixation was performed with (4% paraformaldehyde, 0.2% picric acid, 0.1 M phosphate buffer solution, pH 6.9, TPBS). Immediately after perfusion, the spinal cord was separated and postfixed in the same fixative for 4 hours. And cryoprotection was performed with 30% sucrose (sucrose in PBS, pH 7.4) over 48 hours at refrigerated temperature. The spinal cord was rapidly frozen with siphon gas, and then the L3-L5 spinal cord portion was cut into a 40-m-thick section using a cryostat (manufactured by Microm, Germany). Thereafter, the plate was washed 6 times with TPBS for 5 minutes, quenched with 0.3% H 2 O 2 / TPBS to eliminate the activity of endogenous peroxidase, and washed with 1% goat serum / 0.3% Triton X-100. The reaction was allowed to take place at room temperature for 1 hour to block nonspecific reactions (pre-blocking process). The floating section was reacted with a polyclonal rabbit c-Fos antibody (Calbiochem, 1: 10,000) at 4 ° C. for 24 hours and then washed 6 times with TPBS for 5 minutes, and this section was goatanti-RbIgG which is a secondary antibody. (Vector, 1% NGS / Triton X100 / TPBS 1: 200 dilution) and reacted at room temperature for 1 hour. Thereafter, the plate was washed with TPBS 6 times for 5 minutes, and subjected to a streptavidin (avidin-biotin reaction, 0.3% Tritons X / TPBS 1: 200 dilution) reaction at room temperature for 1 hour, and then with TPBS for 5 minutes. Washed 6 times. C-Fos expression was verified through the 3-3 diamino-benzidine (Sigma Chemicals, USA) reaction. Thereafter, the tissue slice was washed 6 times for 5 minutes each with TPBS, and the tissue section was subjected to a dehydration process using alcohol, followed by a clarification process using xylene. After the arthritis was induced, as a result of evaluating the effect of the white flower serpentine extract (OE) on the expression of Fos protein in the spinal cord, as shown in FIG. 10, compared with the negative control group (A), ibuprofen ( It can be seen that a small amount of Fos protein is observed in B) and the white serpentine grass extract purified product (OE) administration group (C) of the present invention. In addition, as shown in FIGS. 10 and 11, in the negative control group (vehicle), FLI in the right spinal cord caused by chronic pain in the right foot that primarily induced arthritis (Fos-like immune reaction, Fos protein expression) The number of nerve cells and the number of FLI neurons in the left spinal cord that explain the metastasis to the left foot of arthritis are superficial dorsal horn (SDH), spinal nuclei (nucleus proprius, NP), neck of dorsal horn, It can be seen that both increase rapidly at (NECK) sites (Kwon et al., Pain, 90: 271, 2001; Kwon et al., Life Sciences, 71: 191, 2002). In contrast, the white flower serpentine extract and purified product (OE) of the present invention has a shallow layer (SDH), spinal cord proper nucleus (NP), and neck (NECK) sites in both the right and left spinal cords. Decreased almost at the NP site in the left spinal cord than in the right side where arthritis was induced (FIG. 11).
上記の如き結果から、本発明の白花蛇舌草抽出精製物(OE)が一次的に関節炎による疼痛刺激を減少させるだけではなく、関節炎の左足への転移と共に引き起こされる脊髄内への神経性疼痛刺激を効果的に抑制していることが分かる。また、このような痛みに関する神経細胞の活性抑制効果は陽性対照群であるイブプロフェン処置群と類似しており、これは、本発明の白花蛇舌草抽出精製物(OE)が鎮痛効能に優れていることを再確認する結果であることが分かる。 From the results as described above, the white flower serpentine grass extract purified product (OE) of the present invention not only temporarily reduces pain stimulation due to arthritis, but also neural pain into the spinal cord caused by metastasis of arthritis to the left foot. It can be seen that the stimulation is effectively suppressed. In addition, the inhibitory effect on the activity of nerve cells related to such pain is similar to that of the ibuprofen treatment group which is a positive control group. This is because the extract of purified white serpentine grass (OE) of the present invention has an excellent analgesic effect. It turns out that it is the result of reconfirming that it is.
3−4:副作用の評価
(1)体重測定
本発明の白花蛇舌草抽出精製物(OE)が生理現象に副作用を示すかどうかを確認するために、アジュバントの注入後から実験が終了するまで3日おきに体重の変化を測定して体重増加率に対する実験を行った。その結果、図12に示すように、陰性対照群(賦形剤)においては関節炎が誘発された後、9日目を基点として体重増体率が急激に減少することを観察することができた。これは、関節炎が激しくなるに伴い飼料摂取量が減り、飼料を摂取しても疾病による飼料増体率の低下が現れていることを示唆する。また、イブプロフェン処置群も関節炎誘発21日目には関節炎誘発9日目に比較して顕著に体重が減少したが、これは、関節炎が激しくことに伴い現れる増体率の低下であるよりは、内因性シクロオキシゲナーゼの活性低下による胃腸障害に起因するものであると認められる(Whittle, Fundam. Clin. Pharmacol., 17:301, 2003)。これに対し、本発明の白花蛇舌草抽出精製物(OE)処置群の体重増体率は関節炎誘発21日目まで誘発9日目と比較して統計的に有意差を示しておらず、9日目の体重を維持することが分かる。
3-4: Evaluation of side effects (1) Body weight measurement In order to confirm whether or not the white flower serpentine grass extract purified product (OE) of the present invention shows side effects on physiological phenomena, from the injection of adjuvant to the end of the experiment The change in body weight was measured every three days to conduct an experiment on the weight gain rate. As a result, as shown in FIG. 12, in the negative control group (excipient), it was observed that the weight gain rate rapidly decreased starting from day 9 after the induction of arthritis. . This suggests that the amount of feed intake decreases as arthritis becomes severe, and even if the feed is ingested, the decrease in the rate of increase in feed due to disease appears. In addition, the ibuprofen-treated group also showed a significant weight loss on the 21st day after inducing arthritis compared to the 9th day after inducing arthritis. It is considered to be caused by gastrointestinal disorders due to decreased activity of endogenous cyclooxygenase (Whittle, Fundam. Clin. Pharmacol., 17: 301, 2003). In contrast, the weight gain rate of the white flower serpentine extract purified product (OE) treatment group of the present invention does not show a statistically significant difference from the 9th day until the 21st day of arthritis induction, It turns out that the weight of the 9th day is maintained.
前記の如き結果からみて、本発明の白花蛇舌草抽出精製物(OE)は類似する消炎作用を示すイブプロフェンに比べて体重増体率などの基本的な生理現象に副作用がないことが分かる。 From the above results, it can be seen that the white serpentine grass extract and purified product (OE) of the present invention has no side effects on basic physiological phenomena such as weight gain compared to ibuprofen showing similar anti-inflammatory activity.
(2)胃潰瘍形成検査
また、本発明のウルソール酸及びオレアノール酸を含有する白花蛇舌草抽出精製物(OE)が胃腸管系に及ぼす影響を評価するために、実験終了日である21日目にラットを剖検して胃損傷所見を観察した(表3)。病変の頻度は各グループ当たり胃病変を有した動物の数により測定した(n=8)。次により胃粘膜の病変の度合いのステップを分けた。点状出血病変の場合に1点、病変部位が1mmよりも小さければ2点、病変部位が1から2mmであれば3点、病変部位が2から4mmであれば4点、病変部位が4mmよりも大きければ5点にした(Meeroffら、1975)。合計の病変の点数は損傷の度合いによる病変の点数を合算して得た。
(2) Gastric ulcer formation test Further, in order to evaluate the influence of the purified white snake tongue extract (OE) containing ursolic acid and oleanolic acid of the present invention on the gastrointestinal tract, the experiment was completed on the 21st day. Rats were necropsied and observed for gastric damage (Table 3). The frequency of lesions was measured by the number of animals with gastric lesions per group (n = 8). The steps of the degree of gastric mucosal lesion were divided into the following. 1 point for a punctate bleeding lesion, 2 points if the lesion site is smaller than 1 mm, 3 points if the lesion site is 1 to 2 mm, 4 points if the lesion site is 2 to 4 mm, and 4 mm for the lesion site Was also 5 (Meeroff et al., 1975). The total lesion score was obtained by adding the lesion scores according to the degree of damage.
その結果、表3に示すように、既に胃腸障害を誘発するものであると知られているイブプロフェンは、賦形剤群と比較したとき、かなり高い数値の胃損傷の所見を示していたが、本発明のウルソール酸及びオレアノール酸を含む白花蛇舌草抽出精製物(OE)を処置した群は賦形剤群とは統計的に有意差を観察することができなかった。前記の如き結果をまとめてみるとき、本発明の組成物が既に臨床において用いられる薬物と類似する効能を示しながらも、胃腸管内副作用が低いことが分かる。 As a result, as shown in Table 3, ibuprofen, which is already known to induce gastrointestinal disorders, showed a considerably higher value of gastric damage when compared to the excipient group, The group treated with the purified extract of white serpentine grass (OE) containing ursolic acid and oleanolic acid according to the present invention was not able to observe a statistically significant difference from the excipient group. When the above results are summarized, it can be seen that the composition of the present invention has low efficacy in the gastrointestinal tract while exhibiting an effect similar to that of a drug already used in clinical practice.
以上、詳述したように、本発明の消炎及び鎮痛用の組成物は、天然物質由来の物質であって合成物質であるイブプロフェンと同じ消炎及び鎮痛効能を示しつつも、胃腸管系の疾患誘発などの副作用の発生率が低いことから、持続的に治療を受けるべき患者に長期に亘って投与しても安全である。また、本発明による白花蛇舌草抽出精製物の製造方法は、白花蛇舌草から消炎または鎮痛効果に優れた化合物を簡単な方法により高収率にて得られるというメリットがある。なお、本発明によるウルソール酸及びオレアノール酸を一定の割合にて含有する白花蛇舌草抽出精製物は両化合物が共同で作用することにより相乗効果を示し、ウルソール酸またはオレアノール酸を単独にて使用するよりも消炎または鎮痛効果になお一層優れている。 As described above in detail, the anti-inflammatory and analgesic composition of the present invention is a natural substance-derived substance and exhibits the same anti-inflammatory and analgesic efficacy as ibuprofen, which is a synthetic substance, but also induces gastrointestinal diseases. Therefore, it is safe to administer over a long period of time to patients who should be treated continuously. In addition, the method for producing a white flower serpentine extract and purified product according to the present invention has an advantage that a compound excellent in anti-inflammatory or analgesic effect can be obtained from white flower serpentine grass in a high yield by a simple method. In addition, the white flower serpentine extract-purified product containing ursolic acid and oleanolic acid at a certain ratio according to the present invention shows a synergistic effect by the joint action of both compounds, and ursolic acid or oleanolic acid is used alone. It is even better in anti-inflammatory or analgesic effect than it does.
このため、本発明の組成物は関節炎など消炎及び鎮痛のための健康機能食品及び医薬品として有効に利用可能である。 For this reason, the composition of this invention can be effectively used as a health functional food and medicine for anti-inflammatory and analgesic, such as arthritis.
以上、本発明の内容の特定の部分を詳述したが、当分野における通常の知識を有する者にとって、このような具体的な記述は単なる好適な実施様態に過ぎず、これにより本発明の範囲が制限されることはないという点は明らかであろう。よって、本発明の実質的な範囲は特許請求の範囲とこれらの等価物により定まると言えるであろう。 While specific portions of the subject matter of the present invention have been described in detail above, such specific descriptions are merely preferred embodiments for those having ordinary knowledge in the art, and thus the scope of the present invention. It will be clear that is not limited. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (13)
(a)白花蛇舌草を破砕した後、低級アルコール、水、低級有機酸、低級アルコールエステル、低級ケトン、ハロゲン化炭化水素及びこれらの混合物よりなる群から選ばれる溶媒により抽出した後、濃縮するステップ;
(b)前記得られた濃縮物に同量のエチルアセテートを添加した後、2回分画した後に濃縮するステップ;
(c)前記得られた濃縮物にエチルアセテート:アセトン:水を4.25〜4.75:4.25〜4.75:0.5〜1.5の割合にて添加して、30〜60℃の条件において溶解させた後、1〜6℃において保管して沈殿物を生成するステップ;及び
(d)前記沈殿物からウルソール酸及びオレアノール酸を含有する抽出精製物を回収するステップ。 A method for producing an anti-inflammatory or analgesic white serpentine extract extract containing ursolic acid and oleanolic acid, comprising the following steps:
(A) After crushing white flower serpentine grass, it is extracted with a solvent selected from the group consisting of lower alcohol, water, lower organic acid, lower alcohol ester, lower ketone, halogenated hydrocarbon, and mixtures thereof, and then concentrated. Step;
(B) adding the same amount of ethyl acetate to the obtained concentrate, then fractionating twice and then concentrating;
(C) Ethyl acetate: acetone: water was added to the obtained concentrate at a ratio of 4.25 to 4.75: 4.25 to 4.75: 0.5 to 1.5, and 30 to A step of dissolving at 60 ° C. and then storing at 1 to 6 ° C. to form a precipitate; and (d) a step of recovering an extract purified product containing ursolic acid and oleanolic acid from the precipitate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060039925 | 2006-05-03 | ||
PCT/KR2007/001785 WO2007126221A1 (en) | 2006-05-03 | 2007-04-12 | Composition comprising ursolic acid and oleanolic acid for improving and treating arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009534374A true JP2009534374A (en) | 2009-09-24 |
Family
ID=38655710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009506406A Pending JP2009534374A (en) | 2006-05-03 | 2007-04-12 | Anti-inflammatory or analgesic composition comprising white flower serpentine extract extract containing ursolic acid and oleanolic acid |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2009534374A (en) |
KR (1) | KR101084105B1 (en) |
WO (1) | WO2007126221A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017109942A (en) * | 2015-12-15 | 2017-06-22 | 日本製粉株式会社 | Composition for promoting knee joint function improvement action and skeletal muscle function enhancement action by resistance training, comprising oleanane-type triterpene as active ingredient, and using no training equipment |
CN114159406A (en) * | 2021-09-15 | 2022-03-11 | 山东农业大学 | Composite anti-inflammatory nano-particles and preparation method and application thereof |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101031140B1 (en) * | 2008-11-03 | 2011-04-27 | 남종현 | Pharmaceutical composition for preventing and treating cancer and health functional food containing thereof for preventing and improving cancer |
CN101418325B (en) * | 2008-12-03 | 2012-04-04 | 王�琦 | Inonotus obliquus extracellular and incellular mixed exopolysaccharide and preparation method thereof and pharmaceutical use |
JP5313003B2 (en) * | 2009-03-27 | 2013-10-09 | 株式会社ノエビア | Moisturizer |
ITGE20110041A1 (en) * | 2011-04-12 | 2012-10-13 | Ct Di Sperimentazione Ed Assist Enza Agricola | METHOD OF ACHIEVING CARNOSIC ACID AND TRITERPEN, AS PURE COMPOUNDS OR AS ENRICHED PHYTOCOMPLETES, FROM PLANTS OF THE LAMIACEAE FAMILY |
ES2407089B1 (en) * | 2011-11-10 | 2014-06-10 | Consejo Superior De Investigaciones Científicas (Csic) | PENTACYCLIC TRITERPENS TO USE IN THE PREVENTION OR TREATMENT OF ACUTE OR UNDERWARD MIOCARDITIS |
CN102670768A (en) * | 2012-05-15 | 2012-09-19 | 宋协勘 | Traditional Chinese medicine for treating acute appendicitis |
US11241464B2 (en) * | 2013-06-13 | 2022-02-08 | Altera International, Ltd. | Methods of improving reproductive and respiratory health |
CN105029395A (en) * | 2014-04-15 | 2015-11-11 | 四川万安石斛产业开发有限公司 | Food, health-caring product or medicine composition enhancing immunity |
KR102271835B1 (en) | 2014-11-19 | 2021-07-01 | 주식회사 엘지생활건강 | Cosmetics compositions for hair strengthening |
CN108434131A (en) * | 2018-03-01 | 2018-08-24 | 南昌大学 | Herba hedyotis diffusae extract is preparing the application in treating inflammation disease drug |
CN113185567A (en) * | 2021-05-12 | 2021-07-30 | 张洪胜 | Ursolic acid derivative for treating rheumatoid arthritis and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61268648A (en) * | 1985-05-22 | 1986-11-28 | Rooto Seiyaku Kk | Production of oleanolic acid |
JP2002284696A (en) * | 2001-03-28 | 2002-10-03 | Doi Keiko | Therapy for viral, mycotic and other microbial diseases |
JP2004175762A (en) * | 2002-11-28 | 2004-06-24 | Tokio Yazaki | Anticancer agent |
WO2006007487A2 (en) * | 2004-07-01 | 2006-01-19 | E-L Management Corp. | Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100466862B1 (en) * | 2002-01-25 | 2005-01-24 | 주식회사 태평양 | Composition for External Skin Application containing Hedyotis Diffusa Willd Extract |
-
2007
- 2007-04-12 JP JP2009506406A patent/JP2009534374A/en active Pending
- 2007-04-12 WO PCT/KR2007/001785 patent/WO2007126221A1/en active Application Filing
- 2007-04-12 KR KR1020087023992A patent/KR101084105B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61268648A (en) * | 1985-05-22 | 1986-11-28 | Rooto Seiyaku Kk | Production of oleanolic acid |
JP2002284696A (en) * | 2001-03-28 | 2002-10-03 | Doi Keiko | Therapy for viral, mycotic and other microbial diseases |
JP2004175762A (en) * | 2002-11-28 | 2004-06-24 | Tokio Yazaki | Anticancer agent |
WO2006007487A2 (en) * | 2004-07-01 | 2006-01-19 | E-L Management Corp. | Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017109942A (en) * | 2015-12-15 | 2017-06-22 | 日本製粉株式会社 | Composition for promoting knee joint function improvement action and skeletal muscle function enhancement action by resistance training, comprising oleanane-type triterpene as active ingredient, and using no training equipment |
CN114159406A (en) * | 2021-09-15 | 2022-03-11 | 山东农业大学 | Composite anti-inflammatory nano-particles and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2007126221A1 (en) | 2007-11-08 |
KR101084105B1 (en) | 2011-11-16 |
KR20080105140A (en) | 2008-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009534374A (en) | Anti-inflammatory or analgesic composition comprising white flower serpentine extract extract containing ursolic acid and oleanolic acid | |
EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
JP2019511521A (en) | Pharmaceutical composition for the prevention or treatment of respiratory diseases comprising kitsunenomago extract | |
WO2013133649A1 (en) | Use of humulus japonicus extract for preventing or treating metabolic disorders or fatty liver | |
CN112040965B (en) | Composition for preventing, reducing or treating cachexia and muscle loss | |
US8980846B2 (en) | Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma | |
JP6081025B2 (en) | Composition for preventing or treating asthma comprising a monoacetyldiacylglycerol compound as an active ingredient | |
KR102262465B1 (en) | Compositions for preventing or treating allergic disease comprising extracts of Asiasarum sieboldi, Platycodon grandiflorum and Cinnamomum cassia | |
EP3025721B1 (en) | Pharmaceutical composition for preventing or treating asthma comprising pistacia weinmannifolia j. poiss. ex franch extract or fraction thereof | |
CN113813310B (en) | Traditional Chinese medicine composition for preventing and treating brain diseases and preparation method and application thereof | |
KR101758639B1 (en) | A composition of lonicerae caulis, arctii fructus semen and scutellariae radix extracts for treating respiratory disease | |
KR102192586B1 (en) | Phamaceutical composition for treating fatty liver disease and health functional for improving liver function comprising extracts or powder of Pleurotus eryngii var. ferulea (Pf.) | |
KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
KR102079065B1 (en) | Pharmaceutical composition comprising dehydro-6-gingerdione for prevention or treatment of metabolic disease | |
KR102130044B1 (en) | A composition for preventing or treating obesity comprising natural mixture extracts | |
WO2013115534A1 (en) | Composition for preventing or treating multiple sclerosis | |
KR101906208B1 (en) | Pharmaceutical Composition for preventing or treating constipation comprising Liriope platyphylla extract, Glycyrrhiza uralensis Fischer and Chinese Liquorice as an active ingredient | |
KR102627108B1 (en) | Pharmaceutical composition for preventing, improving or treating nonalcoholic fatty liver comprising mixture of Acer tegmentosum Maxim extract and mushroom extract as effective material and manufacturing method for the same | |
CN107106621B (en) | Pharmaceutical composition for preventing or treating neuroinflammation or neurodegenerative disease comprising Portulaca grandiflora extract or fraction thereof as active ingredient | |
JP2020015679A (en) | Compositions for improving lower urinary tract symptoms | |
CN103893512B (en) | A kind of Chinese medicine composition for treating urarthritis | |
WO2021112263A1 (en) | Adiponectin production promoter | |
KR20230054303A (en) | Composition for prevention of pulmonary hypertension, prevention of liver disease caused by pulmonary hypertension, and improvement of liver function and Functional food comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120308 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120612 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120710 |